65 related articles for article (PubMed ID: 16714110)
1. Synthesis and biological activity of nociceptin/orphanin FQ(1-13)NH2 analogues modified in 9 and/or 13 position.
Naydenova ED; Zhivkova VI; Zamfirova RN; Vezenkov LT; Dobrinova YG; Mateeva PI
Bioorg Med Chem Lett; 2006 Aug; 16(15):4071-4. PubMed ID: 16714110
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
J Pept Res; 2004 Jun; 63(6):477-84. PubMed ID: 15175020
[TBL] [Abstract][Full Text] [Related]
3. Are nociceptin(1-13)NH2 and its structural analogue [ORN(9)]nociceptin(1-13)NH2 able to affect brain antioxidant status in control and kainic acid-treated rats?
Tzvetanova E; Pavlova A; Alexandrova A; Nenkova G; Petrov L; Kirkova M; Girchev R; Naydenova E
Cell Biochem Funct; 2009 Jun; 27(4):243-50. PubMed ID: 19418488
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of the activity of newly sinthesized nociceptin / orphanin FQ receptor ligand analogues.
Kasakov L; Nashar M; Naydenova E; Vezenkov L; Vlaskovska M
Protein Pept Lett; 2010 May; 17(5):616-20. PubMed ID: 19689226
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor.
Guerrini R; Caló G; Bigoni R; Rizzi D; Rizzi A; Zucchini M; Varani K; Hashiba E; Lambert DG; Toth G; Borea PA; Salvadori S; Regoli D
J Med Chem; 2001 Nov; 44(23):3956-64. PubMed ID: 11689082
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of new series of N-modified analogues of the N/OFQ(1-13)NH2 with aminophosphonate moiety.
Todorov PT; Mateeva PI; Zamfirova RN; Pavlov ND; Naydenova ED
Amino Acids; 2012 Sep; 43(3):1217-23. PubMed ID: 22143428
[TBL] [Abstract][Full Text] [Related]
7. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.
Guerrini R; Calo G; Rizzi A; Bianchi C; Lazarus LH; Salvadori S; Temussi PA; Regoli D
J Med Chem; 1997 Jun; 40(12):1789-93. PubMed ID: 9191955
[TBL] [Abstract][Full Text] [Related]
8. A structure-activity study of nociceptin-(1-13)-peptide amide. Synthesis of analogues substituted in positions 0, 1, 3, 4 and 10.
Bobrova I; Vlaskovska M; Kasakov L; Surovoy A; Egorova N; Johansson L; Karsnas P; Terenius L
Eur J Med Chem; 2003; 38(7-8):687-94. PubMed ID: 12932899
[TBL] [Abstract][Full Text] [Related]
9. Study of the cytotoxicity and antioxidant capacity of N/OFQ(1-13)NH2 and its structural analogues.
Kirkova M; Zamfirova R; Leśkiewicz M; Kubera M; Lasoń W; Todorov S
Pharmacol Rep; 2009; 61(6):1163-72. PubMed ID: 20081252
[TBL] [Abstract][Full Text] [Related]
10. Nociceptin/Orphanin FQ(1-13)NH2 analogues modified in the Phe1-Gly2 peptide bond.
Guerrini R; Rizzi D; Zucchini M; Tomatis R; Regoli D; Calo' G; Salvadori S
Bioorg Med Chem Lett; 2003 Feb; 13(3):365-8. PubMed ID: 12565930
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship of [Nphe1]-NC-(1-13)-NH2, a pure and selective nociceptin/orphanin FQ receptor antagonist.
Guerrini R; Calo' G; Bigoni R; Rizzi D; Regoli D; Salvadori S
J Pept Res; 2001 Mar; 57(3):215-22. PubMed ID: 11298922
[TBL] [Abstract][Full Text] [Related]
12. High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues.
Charoenchai L; Wang H; Wang JB; Aldrich JV
J Med Chem; 2008 Aug; 51(15):4385-7. PubMed ID: 18624395
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological studies of nociceptin derivatives containing the DTPA chelating group for further labeling with therapeutic radionuclides.
Ligeti M; Gündüz O; Magyar A; Kató E; Rónai AZ; Vita C; Varga I; Hudecz F; Tóth G; Borsodi A; Benyhe S
Peptides; 2005 Jul; 26(7):1159-66. PubMed ID: 15949634
[TBL] [Abstract][Full Text] [Related]
14. Study in vitro and in vivo of nociceptin/orphanin FQ(1-13)NH2 analogues substituting N-Me-Gly for Gly2 or Gly3.
Chen LX; Fang Q; Chen Q; Guo J; Wang ZZ; Chen Y; Wang R
Peptides; 2004 Aug; 25(8):1349-54. PubMed ID: 15350703
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist.
Calo' G; Guerrini R; Bigoni R; Rizzi A; Bianchi C; Regoli D; Salvadori S
J Med Chem; 1998 Aug; 41(18):3360-6. PubMed ID: 9719588
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity profile of new analogues of the cyclic opioid peptide H-Tyr-c[D-Cys-Gly-Phe(pNO2)-D-Cys]-NH2 containing (S)-alpha-hydroxymethylcysteine in place of cysteine.
Witkowska R; Chung NN; Schiller PW; Zabrocki J
J Pept Sci; 2005 Jun; 11(6):361-3. PubMed ID: 15635653
[TBL] [Abstract][Full Text] [Related]
17. Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2.
Carra' G; Calo' G; Spagnolo B; Guerrini R; Arduin M; Marzola E; Trapella C; Regoli D; Salvadori S
J Pept Res; 2005 Jul; 66(1):39-47. PubMed ID: 15946194
[TBL] [Abstract][Full Text] [Related]
18. The mouse vas deferens: a pharmacological preparation sensitive to nociceptin.
Calò G; Rizzi A; Bogoni G; Neugebauer V; Salvadori S; Guerrini R; Bianchi C; Regoli D
Eur J Pharmacol; 1996 Sep; 311(1):R3-5. PubMed ID: 8884244
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of homoarginine-containing opioid peptides.
Izdebski J; Kunce D; Schiller PW; Chung NN; Gers T; Zelman M; Grabek M
J Pept Sci; 2007 Jan; 13(1):27-30. PubMed ID: 16967435
[TBL] [Abstract][Full Text] [Related]
20. Roles of the bed nucleus of stria terminalis and of the amygdala in N/OFQ-mediated anxiety and HPA axis activation.
Green MK; Barbieri EV; Brown BD; Chen KW; Devine DP
Neuropeptides; 2007 Dec; 41(6):399-410. PubMed ID: 17980908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
